* Abcellera Biologics Inc ABCL.OQ reported quarterly
adjusted
earnings of 8 cents per share for the quarter ended in
September. The mean expectation of seven analysts for the
quarter was for earnings of 5 cents per share.
* Revenue rose 1,740.6% to $101.38 million from a year ago;
analysts expected $74.95 million.
* Abcellera Biologics Inc's reported EPS for the quarter was
8
cents.
* The mean earnings estimate of analysts had risen by
about 269.1%
in the last three months.
* In the last 30 days there have been no negative revisions
of
earnings estimates
* Abcellera Biologics Inc shares had risen by 21.4% this
quarter and lost 16.0% so far this year.
* The company reported quarterly net income of $26.62
million.
* Wall Street's median 12-month price target for Abcellera
Biologics Inc is $32.00
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 8 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."
This summary was machine generated from Refinitiv data November
8 at 11:17 p.m. All figures in US dollars unless otherwise
stated. QUARTER ENDING ESTIMATE ACTUAL BEAT, MET,
MISSED
Sep. 30 2022 0.05 0.08 Beat
Jun. 30 2022 -0.02 -0.02 Met
Mar. 31 2022 0.38 0.54 Beat
Dec. 31 2021 0.19 0.19 Met